A radiolabelled derivative incorporating 18F is used to study MAO-B inhibition in both in vivo and in vitro experiments.[4]
Pharmacokinetics
p-Fluoro-L-deprenyl is metabolized to p-fluoro-L-methamphetamine and p-fluoro-L-amphetamine, both of which are active. The levels of substituted amphetamine metabolites in the brain is three times higher following 4-fluoroselegiline administration compared to an equivalent dose of selegiline.[2]
^
abYasar S, Gaal J, Justinova Z, Bergman J (October 2005). "Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys". Psychopharmacology. 182 (1): 95–103.
doi:
10.1007/s00213-005-0063-y.
PMID15990999.
S2CID444126.
^Knoll J, Miklya I (1994). "Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition". Arch Int Pharmacodyn Ther. 328 (1): 1–15.
PMID 7893186.
^Plenevaux A, Fowler JS, Dewey SL, Wolf AP, Guillaume M (January 1991). "The synthesis of no-carrier-added DL-4-[18F]fluorodeprenyl via the nucleophilic aromatic substitution reaction". International Journal of Radiation Applications and Instrumentation, Part A. 42 (2): 121–127.
doi:
10.1016/0883-2889(91)90060-E.
PMID1648033.